Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 5;3(3):CD011571.
doi: 10.1002/14651858.CD011571.pub2.

Antistreptococcal interventions for guttate and chronic plaque psoriasis

Gwendy Dupire  1 , Catherine Droitcourt, Carolyn Hughes, Laurence Le Cleach
Affiliations

Antistreptococcal interventions for guttate and chronic plaque psoriasis

Gwendy Dupire et al. Cochrane Database Syst Rev. .

Abstract

Background: Psoriasis is a chronic skin disease that affects approximately two per cent of the general population. Plaque psoriasis is the most common form: it usually appears as raised, red patches of inflamed skin, covered with silvery white scales. The patches often occur in a symmetrical pattern. Guttate psoriasis is a particular form of psoriasis with widespread, small erythematosquamous lesions. Streptococcal infection is suspected to be a triggering factor for the onset of guttate psoriasis, and flare-up of chronic plaque psoriasis. The previous Cochrane Review on this topic was published in 2000; it required an update because antistreptococcal treatment continues to be used to treat psoriasis, especially for the acute form of guttate psoriasis.

Objectives: To assess the effects of antistreptococcal interventions for guttate and chronic plaque psoriasis.

Search methods: We searched Cochrane Skin Specialised Register, Cochrane Register of Studies Online, CENTRAL, MEDLINE, Embase, LILACS, and five trials registers (January 2019). We checked the reference lists of included and excluded studies and searched conference proceedings from the American Academy of Dermatology, Society for Investigative Dermatology, and European Academy of Dermatology and Venereology.

Selection criteria: We considered randomised controlled trials (RCTs) assessing antistreptococcal interventions (tonsillectomy or systemic antibiotic treatment) in people with clinically diagnosed acute guttate and chronic plaque psoriasis compared with placebo, no intervention, or each other.

Data collection and analysis: We used standard methodological procedures expected by Cochrane. Primary outcome measures were: 1) time-to-resolution; achieving clear or almost clear skin (Physician Global Assessment (PGA) 0 or 1 or Psoriasis Area and Severity Index (PASI) 90 or 100); 2) proportion of participants with adverse effects and severe adverse effects. Secondary outcomes were: 1) proportion of participants achieving clear or almost clear skin; 2) proportion of participants achieving PASI 75 or PGA 1 to 2; 3) risk of having at least one relapse at long-term follow-up. Short-term assessment was defined as within eight weeks of the start of treatment; long-term was at least one year after the start of treatment.

Main results: We included five trials (162 randomised participants); three were conducted in a hospital dermatology department. One study declared funding by a pharmaceutical company. Participants' ages ranged from 12 to 77 years; only two participants were younger than 15 years. Mean PASI score at baseline varied from 5.7 (i.e. mild) to 23 (i.e. severe) in four studies. Twenty-three of 162 participants had streptococcus-positive throat swab culture. We did not perform a meta-analysis due to heterogeneity of participants' characteristics and interventions.None of the trials measured our efficacy primary outcome, time-to-resolution, or the secondary outcome, risk of having at least one relapse at long-term follow-up.We rated the quality of the results as very low-quality evidence, due to high risk of bias (absence of blinding of participants and caregivers, and high risk of outcome reporting bias) and imprecision (single study data with a low number of events). Hence, we are very uncertain about the results presented.Guttate psoriasisOne three-armed trial (N = 43) assessed penicillin (50,000 international units (IU)/kg/day in three doses) versus erythromycin (250 mg four times per day) versus no treatment (treatment for 14 days, with six-week follow-up from start of treatment). Adverse events and the proportion of participants achieving clear or almost clear skin were not measured.One trial (N = 20) assessed penicillin (1.6 MU (million units) intramuscularly once a day) versus no treatment (six weeks of treatment, with eight-week follow-up from start of treatment). At six-week (short-term) follow-up, no adverse events were observed in either group, and there was no statistically significant difference between the two groups in the proportion of participants with clear or almost clear skin (risk ratio (RR) 2.00, 95% confidence interval (CI) 0.68 to 5.85).One trial (N = 20) assessed rifampicin (300 mg twice daily) versus placebo (14-day treatment duration; six-week follow-up from start of treatment); none of the review outcomes were measured.These trials did not measure the proportion of participants achieving PASI 75 or PGA 1 to 2.Chronic plaque psoriasisOne trial (N = 50) assessed long-term azithromycin treatment (500 mg daily dose) versus vitamin C. Adverse events were reported in the azithromycin group (10 out of 30 had nausea and mild abdominal upset), but not in the vitamin C group. The proportion of participants who achieved clear or almost clear skin was not measured. In the azithromycin group, 18/30 versus 0/20 participants in the vitamin C group reached PASI 75 at the end of 48 weeks of treatment (RR 25.06, 95% CI 1.60 to 393.59).One trial (N = 29) assessed tonsillectomy versus no treatment, with 24-month follow-up after surgery. One participant in the tonsillectomy group had minor bleeding. At eight-week follow-up, 1/15 in the tonsillectomy group, and 0/14 in the no treatment group achieved PASI 90; and 3/15 participants in the tonsillectomy group, and 0/14 in the no treatment group achieved PASI 75 (RR 6.56, 95% CI 0.37 to 116.7).

Authors' conclusions: We found only five trials (N = 162), which assessed the effects of five comparisons (systemic antibiotic treatment (penicillin, azithromycin) or tonsillectomy). Two comparisons (erythromycin compared to no treatment, and rifampicin compared to placebo) did not measure any of the outcomes of interest. There was very low-quality evidence for the outcomes that were measured, Therefore, we are uncertain of both the efficacy and safety of antistreptococcal interventions for guttate and chronic plaque psoriasis.The included trials were at unclear or high risk of bias and involved only a small number of unrepresentative participants, with limited measurement of our outcomes of interest. The studies did not allow investigation into the influence of Streptococcal infection, and a key intervention (amoxicillin) was not assessed.Further trials assessing the efficacy and tolerance of penicillin V or amoxicillin are needed in children and young adults with guttate psoriasis.

PubMed Disclaimer

Conflict of interest statement

Gwendy Dupire: nothing to declare. Catherine Droitcourt: nothing to declare. Carolyn Hughes: nothing to declare. Laurence Le Cleach: nothing to declare.

Ruth Murphy (clinical referee): "I have taken part in an advisory board with Novartis about disease prevention in Psoriasis in October 2017."

Figures

1
1
Flow diagram describing the searches and screening of studies
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study
1.1
1.1. Analysis
Comparison 1 Penicillin versus no treatment in guttate psoriasis, Outcome 1 Proportion of participants achieving clear or almost clear skin (PASI 90 or 100 or PGA 0 or 1).
2.1
2.1. Analysis
Comparison 2 Oral azithromycin versus vitamin C in chronic plaque psoriasis, Outcome 1 Proportion of participants achieving PASI 75 or PGA 1 to 2.
3.1
3.1. Analysis
Comparison 3 Tonsillectomy versus no intervention in chronic plaque psoriasis, Outcome 1 Number of participants with adverse events or severe adverse events.
3.2
3.2. Analysis
Comparison 3 Tonsillectomy versus no intervention in chronic plaque psoriasis, Outcome 2 Proportion of participants achieving clear or almost clear skin (PASI 90 or 100 or PGA 0 or 1).
3.3
3.3. Analysis
Comparison 3 Tonsillectomy versus no intervention in chronic plaque psoriasis, Outcome 3 Proportion of participants achieving PASI 75 or PGA 1 to 2.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Caca‐Biljanovska 2002 {published data only}
    1. Caca‐Biljanovska NG, V'lckova‐Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croatian Medical Journal 2002;43(6):707‐12. [CENTRAL: CN‐00412128; PUBMED: 12476481] - PubMed
Dogan 2008 {published data only}
    1. Dogan B, Karabudak O, Harmanyeri Y. Antistreptococcal treatment of guttate psoriasis: a controlled study. International Journal of Dermatology 2008;47(9):950‐2. [CENTRAL: CN‐00665439; PUBMED: 18937661] - PubMed
Saxena 2010 {published data only}
    1. Saxena VN, Dogra J. Long‐term oral azithromycin in chronic plaque psoriasis: a controlled trial. European Journal of Dermatology 2010;20(3):329‐33. [CENTRAL: CN‐00750715; PUBMED: 20299307] - PubMed
Thorleifsdottir 2012 {published and unpublished data}
    1. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, Olafsson JH, Sigurdsson MI, Petersen H, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. Journal of Immunology 2012;188(10):5160‐5. [CENTRAL: CN‐00969900; PUBMED: 22491250] - PubMed
    1. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, Olafsson JH, Sigurdsson MI, Petersen H, et al. Patient‐reported outcomes and clinical response in patients with moderate‐to‐severe plaque psoriasis treated with tonsillectomy: a randomized controlled trial. Acta Dermato‐Venereologica 2017;97(3):340‐5. [CENTRAL: CN‐01336830; PUBMED: 27819714] - PubMed
    1. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, Olafsson JH, Sigurgeirsson B, Petersen H. The impact of tonsillectomy on patients with chronic plaque psoriasis. European Journal of Immunology 2009;39(S1):S311. [CENTRAL: CN‐00784461; DOI: 10.1002/eji.200990152] - DOI
Vincent 1992 {published data only}
    1. Vincent F, Ross JB, Dalton M, Wort AJ. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. Journal of the American Academy of Dermatology 1992;26(3 Pt 2):458‐61. [CENTRAL: CN‐00083299; PUBMED: 1564153] - PubMed

References to studies excluded from this review

Falagas 2008 {published data only}
    1. Falagas ME, Vouloumanou EK, Matthaiou DK, Kapaskelis AM, Karageorgopoulos DE. Effectiveness and safety of short‐course vs long‐course antibiotic therapy for group a beta hemolytic streptococcal tonsillopharyngitis: a meta‐analysis of randomized trials. Mayo Clinic Proceedings 2008;83(8):880‐9. [PUBMED: 18674472] - PubMed
Forstrom 1974 {published data only}
    1. Forstrom L, Lassus A. Fucidic acid and psoriasis. Annals of clinical research 1974;6(3):165‐6. [CENTRAL: CN‐00010569; PUBMED: 4844128] - PubMed
Gudjonsson 2003 {published data only}
    1. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. British Journal of Dermatology 2003;149(3):530‐4. [CENTRAL: CN‐00457920; PUBMED: 14510985] - PubMed
Komine 2000 {published data only}
    1. Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. Journal of Dermatology 2000;27(8):508‐12. [PUBMED: 10989574] - PubMed
Kurwa 1973 {published data only}
    1. Kurwa A, Abdel‐Aziz AH. Preliminary clinical trial of fusidic acid in psoriasis. British Journal of Clinical Practice 1973;27(3):92‐4. [PUBMED: 4580210] - PubMed
Masood 1997 {published data only}
    1. Masood Q, Manzoor S. Treatment of psoriasis with penicillin. JK Practitioner 1997;4(3):178‐9. [EMBASE: 1997226265]
Nyfors 1973 {published data only}
    1. Nyfors A. Fucidin in psoriasis. A double‐blind study of twenty psoriatics over two periods of four weeks each. Dermatologica 1973;146(5):281‐4. [CENTRAL: CN‐00009169; PUBMED: 4583782] - PubMed
Owen 2001 {published data only}
    1. Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. British Journal of Dermatology 2001;145(6):886‐90. [PUBMED: 11899140] - PubMed
Rappersberger 1996 {published data only}
    1. Rappersberger K, Meingassner JG, Fialla R, Fodinger D, Sterniczky B, Rauch S, et al. Clearing of psoriasis by a novel immunosuppressive macrolide. Journal of Investigative Dermatology 1996;106(4):701‐10. [CENTRAL: CN‐00123674; PUBMED: 8618008] - PubMed
Raza 2007 {published data only}
    1. Raza N, Usman M, Hameed A. Chronic plaque psoriasis: streptococcus pyogenes throat carriage rate and therapeutic response to oral antibiotics in comparison with oral methotrexate. Journal of the College of Physicians and Surgeons – Pakistan: JCPSP 2007;17(12):717‐20. [CENTRAL: CN‐01093552; PUBMED: 18182134] - PubMed
Rosenberg 1986 {published data only}
    1. Rosenberg EW, Noah PW, Zanolli MD, Skinner RB Jr, Bond MJ, Crutcher N. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report. Journal of the American Academy of Dermatology 1986;14(5 Pt 1):761‐4. [CENTRAL: CN‐00366543; PUBMED: 3086388] - PubMed
Stutz 1996 {published data only}
    1. Stutz JA, Ellis CN, Kang S. Failure of topical polymyxin B to improve mild plaque psoriasis. Archives of Dermatology 1996;132(2):231. [CENTRAL: CN‐00124927; PUBMED: 8629837] - PubMed
Tsankov 2011 {published data only}
    1. Grozdev I, Kazandjieva J, Tsankov N. New insights of rifampicin in psoriasis. Journal of the European Academy of Dermatology and Venereology: JEADV 2010;24(Suppl 4):11‐2. [EMBASE: 70238697]
    1. Tsankov N, Grozdev I. Rifampicin in the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology: JEADV 2009;23(1):93‐5. [PUBMED: 18384550] - PubMed
    1. Tsankov N, Grozdev I. Rifampicin – a mild immunosuppressive agent for psoriasis. Journal of Dermatological Treatment 2011;22(2):62‐4. [PUBMED: 20653488] - PubMed
    1. Tsankov N, Grozdev I, Kkzandjieva J. Old drug – new indication. Rifampicin in psoriasis. Journal of Dermatological Treatment 2006;17(1):18‐23. [CENTRAL: CN‐00555057; PUBMED: 16467019] - PubMed

References to studies awaiting assessment

NCT00427609 {unpublished data only}
    1. NCT00427609. Bicillin L‐A vs placebo for the treatment of chronic, plaque‐type psoriasis unresponsive to topical medications. clinicaltrials.gov/ct2/show/NCT00427609 (first received 25 January 2007).

Additional references

Abe 1991
    1. Abe J, Forrester J, Nakahara T, Lafferty JA, Kotzin BL, Leung DY. Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. Journal of Immunology 1991;146(11):3747‐50. [MEDLINE: ] - PubMed
Augustin 2013
    1. Augustin M, Reich K, Glaeske G, Kampfe S, Radtke MA, Gerdau‐Heitmann C, et al. Drug supply for children with psoriasis in Germany. Journal der Deutschen Dermatologischen Gesellschaft – Journal of the German Society of Dermatology: JDDG 2013;11(8):751‐5. [PUBMED: 23718227] - PubMed
Baugh 2011
    1. Baugh RF, Archer SM, Mitchell RB, Rosenfeld RM, Amin R, Burns JJ, et al. Clinical practice guideline: tonsillectomy in children. Otolaryngology – Head & Neck surgery 2011;144(1 Suppl):S1‐30. [MEDLINE: ] - PubMed
Berth‐Jones 2005
    1. Berth‐Jones J. Psoriasis. Medicine 2005;33(1):50‐5.
Burton 2009
    1. Burton MJ, Glasziou PP. Tonsillectomy or adeno‐tonsillectomy versus non‐surgical treatment for chronic/recurrent acute tonsillitis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD001802.pub2] - DOI - PubMed
Chalmers 2001
    1. Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. A systematic review of treatments for guttate psoriasis. British Journal of Dermatology 2001;145(6):891‐4. [MEDLINE: ] - PubMed
De Jager 2009
    1. Jager ME, Kerkhof PC, Jong EM, Seyger MM. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals. Journal of Dermatological Treatment 2009;20(5):254‐8. [PUBMED: 19418330] - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997;315(7109):629‐34. [PUBMED: 9310563] - PMC - PubMed
Elder 2010
    1. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: integrating genetics and biology. Journal of Investigative Dermatology 2010;130(5):1213‐26. [MEDLINE: ] - PubMed
Ferran 2013
    1. Ferran M, Galvan AB, Rincon C, Romeu ER, Sacrista M, Barboza E, et al. Streptococcus induces circulating CLA(+) memory T‐cell‐dependent epidermal cell activation in psoriasis. Journal of Investigative Dermatology 2013;133(4):999‐1007. [MEDLINE: ] - PubMed
GHDx 2018
    1. Global Health Data Exchange (GHDx). GBD Results Tool. ghdx.healthdata.org/gbd‐results‐tool (accessed 22 January 2019).
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 10 April 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Griffiths 2007
    1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370(9583):263‐71. [MEDLINE: ] - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Horton 2016
    1. Horton DB, Scott FI, Haynes K, Putt ME, Rose CD, Lewis JD, et al. Antibiotic exposure, infection, and the development of pediatric psoriasis: a nested case‐control study. JAMA Dermatology 2016;152(2):191‐9. [PUBMED: 26560335] - PMC - PubMed
Ko 2010
    1. Ko HC, Jwa SW, Song M, Kim MB, Kwon KS. Clinical course of guttate psoriasis: long‐term follow‐up study. Journal of Dermatology 2010;37(10):894‐9. [MEDLINE: ] - PubMed
Kotzin 1993
    1. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Advances in Immunology 1993;54:99‐166. [MEDLINE: ] - PubMed
Kundakci 2002
    1. Kundakci N, Tursen U, Babiker MO, Gurgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. International Journal of Dermatology 2002;41(4):220‐4. [MEDLINE: ] - PubMed
Kwon 2012
    1. Kwon HH, Na SJ, Jo SJ, Youn Jl. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. Journal of Dermatology 2012;39(3):260‐4. [MEDLINE: ] - PubMed
Laing 1991
    1. Laing MR, McKerrow WS. Adult tonsillectomy. Clinical Otolaryngology and Allied Sciences 1991;16(1):21‐4. [PUBMED: 2032352] - PubMed
Le Cleach 2011
    1. Cleach L, Trinquart L, Lebrun‐Vignes B, Giraudeau B, Chosidow O. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD009036] - DOI - PMC - PubMed
Ledoux 2009
    1. Ledoux M, Chazerain V, Saiag P, Mahe E. Streptococcal perianal dermatitis and guttate psoriasis [Anite streptococcique et psoriasis en gouttes]. Annales de Dermatologie et de Venereologie 2009;136(1):37‐41. [MEDLINE: ] - PubMed
Leung 1995
    1. Leung DY, Travers JB, Giorno R, Norris DA, Skinner R, Aelion J, et al. Evidence for a streptococcal superantigen‐driven process in acute guttate psoriasis. Journal of Clinical Investigation 1995;96(5):2106‐12. [MEDLINE: ] - PMC - PubMed
Mahe 2018
    1. Mahe E, Bursztejn AC, Phan A, Corgibet F, Beauchet A. Management of childhood psoriasis in France. A national survey among general practitioners, pediatricians, and dermatologists. Dermatologic Therapy 2018;31(1):1‐8. [PUBMED: 29193624] - PubMed
Martin 1996
    1. Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?. Archives of Dermatology 1996;132(6):717‐8. [MEDLINE: ] - PubMed
Mercy 2013
    1. Mercy K, Kwasny M, Cordoro KM, Menter A, Tom WL, Korman N, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatric Dermatology 2013;30(4):424‐8. [PUBMED: 23360462] - PMC - PubMed
Moher 2010
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel groups randomised trials. Journal of Clinical Epidemiology 2010;63(8):834‐40. [PUBMED: 20346629] - PubMed
Newman 2008
    1. Newman MD, Weinberg JM. The pathophysiology of psoriasis. In: Weinberg JM editor(s). Treatment of Psoriasis. Basel: Birkhauser, 2008:11‐21. [ISBN 978‐3‐7643‐7722‐9]
NICE 2017
    1. National Institute for Health Care and Excellence. Psoriasis: assessment and management. www.nice.org.uk/guidance/cg153 (accessed prior to 19 February 2019).
Norrlind 1955
    1. Norrlind R. The significance of infections in the origination of psoriasis. Acta Rheumatologica Scandinavica 1955;1(2):135‐44. [PUBMED: 13248712] - PubMed
Paradise 1984
    1. Paradise JL, Bluestone CD, Bachman RZ, Colborn DK, Bernard BS, Taylor FH, et al. Efficacy of tonsillectomy for recurrent throat infection in severely affected children. Results of parallel randomized and nonrandomized clinical trials. New England Journal of Medicine 1984;310(11):674‐83. [PUBMED: 6700642] - PubMed
Parisi 2013
    1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. The Journal of Investigative Dermatology 2013;133(2):377‐85. [PUBMED: 23014338] - PubMed
Picciani 2013
    1. Picciani BL, Michalski‐Santos B, Carneiro S, Sampaio AL, Avelleira JC, Azulay DR, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. Journal of the American Academy of Dermatology 2013;68(6):986‐91. [MEDLINE: ] - PubMed
Rachakonda 2015
    1. Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW. Effect of tonsillectomy on psoriasis: a systematic review. Journal of the American Academy of Dermatology 2015;72(2):261‐75. [PUBMED: 25455609] - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rigopoulos 2010
    1. Rigopoulos D, Gregoriou S, Katrinaki A, Korfitis C, Larios G, Stamou C, et al. Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climate. European Journal of Dermatology 2010;20(2):189‐95. [MEDLINE: ] - PubMed
Shulman 2012
    1. Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2012;55(10):1279‐82. [PUBMED: 23091044] - PubMed
SIGN 2010
    1. Scottish Intercollegiate Guidelines Network. Management of sore throat and indications for tonsillectomy. Guideline No 117, April 2010. www.sign.ac.uk/guidelines/fulltext/117/index.html (accessed 8 May 2014).
Tanz 2007
    1. Tanz RR, Shulman ST. Chronic pharyngeal carriage of group A streptococci. Pediatric Infectious Disease Journal 2007;26(2):175‐6. [PUBMED: 17259882] - PubMed
Telfer 1992
    1. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Archives of Dermatology 1992;128(1):39‐42. [MEDLINE: ] - PubMed
Tervaert 1970
    1. Tervaert WC, Esseveld H. A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris, with reference to their role in the pathogenesis of this disease. Dermatologica 1970;140(5):282‐90. [MEDLINE: ] - PubMed
Valdimarsson 1997
    1. Valdimarsson H, Sigmundsdottir H, Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M‐protein‐specific T cells that cross‐react with keratin?. Clinical & Experimental Immunology 1997;107(Suppl 1):21‐4. [MEDLINE: ] - PubMed
Valenzuela 2011
    1. Valenzuela F, Silva P, Valdes MP, Papp K. Epidemiology and quality of life of patients with psoriasis in Chile. Actas Dermo‐Sifiliograficas 2011;102(10):810‐6. [MEDLINE: ] - PubMed
Vogel 2012
    1. Vogel SA, Yentzer B, Davis SA, Feldman SR, Cordoro KM. Trends in pediatric psoriasis outpatient health care delivery in the United States. Archives of Dermatology 2012;148(1):66‐71. [PUBMED: 21931013] - PubMed
Whyte 1964
    1. Whyte HJ, Baughman RD. Acute guttate psoriasis and streptococcal infection. Archives of Dermatology 1964;89:350‐6. [MEDLINE: ] - PubMed
Williams 1976
    1. Williams RC, McKenzie AW, Roger JH, Joysey VC. HL‐A antigens in patients with guttate psoriasis. British Journal of Dermatology 1976;95(2):163‐7. [MEDLINE: ] - PubMed
Wolff 2009
    1. Wolff K, Johnson RA, Fitzpatrick TB. Psoriasis. In: Wolff K, Johnson RA editor(s). Fitzpatrick's Color Atlas & Synopsis of Clinical Dermatology. 6th Edition. New York: McGraw‐Hill Medical, 2009:53‐7. [ISBN 978‐0‐07‐159975‐7]

References to other published versions of this review

Dupire 2015
    1. Dupire G, Droitcourt C, Ferneiny M, Hughes C, Katsahian S, Cleach L. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD011571] - DOI - PMC - PubMed
Owen 2000
    1. Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD001976] - DOI - PubMed

Publication types